null Option on BioCryst Pharmaceuticals

BCRX Stock  USD 8.61  0.09  1.03%   
BioCryst Pharmaceuticals' latest option contracts expiring on September 19th 2025 are carrying combined implied volatility of 1.16 with a put-to-call open interest ratio of 0.08 over 35 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on September 19th 2025. The total put volume is at 3.0, with calls trading at the volume of 44.0. This yields a 0.07 put-to-call volume ratio.

Open Interest Against September 19th 2025 Option Contracts

BioCryst Pharmaceuticals option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in BioCryst Pharmaceuticals' lending market. For example, when BioCryst Pharmaceuticals' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on BioCryst Pharmaceuticals, he or she must hedge the risk by shorting BioCryst Pharmaceuticals stock over its option's life.
The chart above shows BioCryst Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. BioCryst Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for BioCryst Pharmaceuticals' option, there is no secondary market available for investors to trade.

In The Money vs. Out of Money Option Contracts on BioCryst Pharmaceuticals

Analyzing BioCryst Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in BioCryst Pharmaceuticals regardless of its overall volatility. This is especially true when BioCryst Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money BioCryst Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with BioCryst Pharmaceuticals' stock while costing only a fraction of its price.

BioCryst Pharmaceuticals In The Money Call Balance

When BioCryst Pharmaceuticals' strike price is surpassing the current stock price, the option contract against BioCryst Pharmaceuticals stock is said to be in the money. When it comes to buying BioCryst Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on BioCryst Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

BioCryst Current Options Market Mood

BioCryst Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps BioCryst Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Unfortunately, most BioCryst Pharmaceuticals' options investors are not very successful. BioCryst Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current BioCryst contract

Base on the Rule 16, the options market is currently suggesting that BioCryst Pharmaceuticals will have an average daily up or down price movement of about 0.0725% per day over the life of the 2025-09-19 option contract. With BioCryst Pharmaceuticals trading at USD 8.61, that is roughly USD 0.006242. If you think that the market is fully incorporating BioCryst Pharmaceuticals' daily price movement you should consider buying BioCryst Pharmaceuticals options at the current volatility level of 1.16%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing BioCryst Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" BioCryst calls. Remember, the seller must deliver BioCryst Pharmaceuticals stock to the call owner when a call is exercised.

BioCryst Pharmaceuticals Option Chain

When BioCryst Pharmaceuticals' strike price is surpassing the current stock price, the option contract against BioCryst Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
BioCryst Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on BioCryst. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for BioCryst. It also shows strike prices and maturity days for a BioCryst Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
BCRX250919C00021000021.00.0 - 0.750.75Out
Call
BCRX250919C00020000020.00.0 - 0.750.75Out
Call
BCRX250919C00019000019.00.0 - 0.750.75Out
Call
BCRX250919C00018000018.00.0 - 0.750.75Out
Call
BCRX250919C00017000017.00.0 - 0.750.75Out
Call
BCRX250919C000160001016.00.0 - 0.750.75Out
Call
BCRX250919C000150001915.00.0 - 0.750.75Out
Call
BCRX250919C000140006514.00.0 - 0.750.15Out
Call
BCRX250919C0001300041413.00.0 - 0.150.1Out
Call
BCRX250919C0001200065812.00.0 - 0.150.1Out
Call
BCRX250919C0001100077811.00.05 - 0.20.07Out
Call
BCRX250919C0001000084610.00.15 - 0.30.23Out
Call
BCRX250919C000090002439.00.45 - 0.50.48Out
Call
BCRX250919C0000800033208.00.05 - 1.21.0In
Call
BCRX250919C00007000597.01.35 - 2.22.19In
Call
BCRX250919C00006000216.02.35 - 3.13.1In
Call
BCRX250919C0000400014.04.1 - 5.15.85In
Call
BCRX250919C0000300083.05.1 - 6.05.9In
Call
BCRX250919C00002000272.05.9 - 7.65.9In
 Put
BCRX250919P00021000021.012.0 - 14.612.0In
 Put
BCRX250919P00020000020.011.2 - 11.511.2In
 Put
BCRX250919P00019000019.09.1 - 12.39.1In
 Put
BCRX250919P00018000018.09.0 - 9.99.0In
 Put
BCRX250919P00017000017.08.0 - 8.58.0In
 Put
BCRX250919P00016000016.07.0 - 9.57.0In
 Put
BCRX250919P00015000215.06.0 - 7.66.0In
 Put
BCRX250919P00014000014.05.3 - 5.55.3In
 Put
BCRX250919P00013000013.04.0 - 6.52.37In
 Put
BCRX250919P00012000012.02.9 - 4.12.9In
 Put
BCRX250919P0001100024511.02.25 - 4.92.2In
 Put
BCRX250919P000100008910.00.0 - 4.31.35In
 Put
BCRX250919P00009000339.00.5 - 0.950.8In
 Put
BCRX250919P00008000438.00.0 - 0.450.35Out
 Put
BCRX250919P000070001067.00.0 - 0.60.25Out
 Put
BCRX250919P00006000106.00.0 - 0.70.7Out

BioCryst Pharmaceuticals Selling And Marketing Expenses Over Time

   Selling And Marketing Expenses   
       Timeline  

BioCryst Total Stockholder Equity

Total Stockholder Equity

(452.14 Million)

BioCryst Pharmaceuticals reported Total Stockholder Equity of (475.93 Million) in 2024

BioCryst Pharmaceuticals Corporate Management

Yarlagadda BabuSr. VP of Drug DiscoveryProfile
Alane BarnesVP, General Counsel and Corporate SecretaryProfile
Elliott BergerVP AffairsProfile
William MBBSChief OfficerProfile
Stephanie AngeliniChief OfficerProfile
Michael JonesExecutive OfficerProfile
Clayton FletcherChief OfficerProfile

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.